Richard B Moss M.D.
Professor Emeritus Pediatrics, Stanford University Medical Center
Richard B. Moss MD is Professor Emeritus at Stanford University School of Medicine in the Department of Pediatrics' Center for Excellence in Pulmonary Biology. He is former chief of the pediatric pulmonary and allergy-immunology divisions, and former allergy-immunology and pulmonary fellowship training programs director at Stanford Children's Health/Lucile Packard Children's Hospital Stanford. He was educated and trained at Columbia (BA), SUNY Downstate (MD), Children's Memorial Hospital of Northwestern University (pediatric residency) and Stanford (allergy-immunology and ATS pulmonology fellowships). He was Director of the Stanford Cystic Fibrosis Center from 1991 to 2009 and principal investigator for the Cystic Fibrosis Foundation's Therapeutics Development Network (TDN), where he also served as the inaugural Chair of the TDN Protocol Review Committee. He has served on CFF's Clinical Research Committee, Translational Advisory Group and Clinical Research Advisory Board. He has been a member of Stanford's Child Health Research Institute and has served on Stanford's Pediatric Mentoring Program for trainees and junior faculty, the Executive Committee of Spectrum Child Health (Stanford's NIH-funded clinical research program) and Stanford University IRB. He has been on CFRI's Board of Directors since 2015. Dr. Moss has reviewed widely for the NIH as well as CFF and international research granting agencies and foundations in the US, Canada, UK, Germany, Italy and elsewhere, and consulted for many biomedical journals and biotechnology-pharmaceutical companies. He has published over 260 peer-reviewed original research papers and is a frequent speaker at national and international medical conferences. His research interests have included pathogenesis, outcome measures, and treatment of chronic airway diseases of childhood including asthma, CF and bronchopulmonary dysplasia, with an emphasis on mechanisms of pulmonary immunity, inflammation and allergy. Recent work has focused on allergic fungal lung disease such as allergic bronchopulmonary mycoses, and clinical testing of novel CF diagnostic and outcome tests and treatments.